Yazar "Bayram, Fahri" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ N/A ]
    Öğe
    Increased Density of Demodex Folliculorum May be Related to Additional Risk Factors Reply
    (Acad Medical Sciences I R Iran, 2016) Dokuyucu, Recep; Kaya, Ozlem Aycan; Yula, Erkan; Ustun, Ihsan; Bayram, Fahri; Gokce, Cumali
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    The Presence of Demodex Folliculorum in Various Obese Groups According to BMI Levels
    (Acad Medical Sciences I R Iran, 2016) Dokuyucu, Recep; Kara, Ozlem Aycan; Yula, Erkan; Ustun, Ihsan; Bayram, Fahri; Gokce, Cumali
    Background: This study aimed to detect the presence of the parasite Demodex folliculorum (DF) in various obese groups according to BMI Levels. Materials and Methods: A total of 182 patients (40.8 +/- 14.8 years, min-max age 19=73 years) were enrolled in the study, of those 65 (35.7%) were female and 117 (64.3%) were male. They had previously applied to Mustafa Kemal University (Faculty of Medidne, Endocrine Outpatient Clinic) during 2012. A standardized skin surface biopsy method was used to research the existence of DF. Patients were classified into four main groups, including: obese (n = 89), overweight (n = 31), normal (n = 32), and underweight (n = 30). Results: There was no significant difference between groups in terms of age and sex. The total DF positivity was 19 (21.3%) in obese patients. Among those with positive DF, the mean BMI was 35.7 +/- 12.1 kg/m(2), while Those with negative DF had a mean BMI of 29.2 +/- 9.2 kg/m(2). There was a significant difference between two groups (P = 0.002). Also, the underweight group has significantly higher DF positivity in comparison to the normal weight group. Conclusion: The DF positivity was significantly higher in obese patients in accordance with the physiopathologic nature of the disease.
  • [ N/A ]
    Öğe
    Re: Increased density of demodex folliculorum may be related to additional risk factors
    (Academy of Medical Sciences of I.R. Iran, 2016) Dokuyucu, Recep; Kaya, Ozlem Aycan; Yula, Erkan; Ustun, Ihsan; Bayram, Fahri; Gokce, Cumali
    [No abstract available]
  • [ N/A ]
    Öğe
    Toxoplasma gondii antibodies in type 1 Diabetes mellitus
    (Ortadogu Ad Pres & Publ Co, 2008) Goekce, Cumali; Yazar, Sueleyman; Bayram, Fahri; Guendogan, Kursat
    Objective: Toxoplasma gondii is a protozoan parasite, which infects Lip to a third of the world's population. Infections are more common and run a more protracted course in patients with Diabetes mellitus (DM). We aimed to determine the prevalence of anti-T. gondii antibodies in patients with type 1 DM. Material and Methods: The study group comprised 85 patients with type 1 DM and 85 healthy volunteers. Micro enzyme-linked ininiunosorbent assay and indirect fluorescent antibody technique were used. Results: T. gondii IgG sero-positivity rate in DM patients (56.62%) was significantly higher than in controls (22.4%). Conclusion: Parasitologic surveys should be repeated periodically in this group of patients.
  • Küçük Resim
    Öğe
    Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study)
    (Elsevier Ireland Ltd, 2018) Sonmez, Alper; Haymana, Cem; Bayram, Fahri; Salman, Serpil; Dizdar, Oguzhan Sitki; Gurkan, Eren; Carlioglu, Ayse Kargili
    Aims: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus. Methods: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c <7%, home arterial blood pressure (ABP) <135/85 mmHg, or LDL-C <100 mg/dL. Achieving all parameters indicated triple metabolic control. Results: HbA1c levels of patients (n = 5211) were 8.6 +/- 1.9% (71 +/- 22 mmol/mol) and 7.7 +/- 1.7% (61 +/- 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, nonsmoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups. Conclusions: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease. (C) 2018 Elsevier B.V. All rights reserved.
  • Küçük Resim
    Öğe
    Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes-a nationwide cross-sectional study (TEMD dyslipidemia study)
    (Bmc, 2020) Bayram, Fahri; Sonmez, Alper; Haymana, Cem; Sabuncu, Tevfik; Dizdar, Oguzhan Sitki; Gurkan, Eren; Carlioglu, Ayse Kargili
    Background Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians' attitudes on the treatment of diabetic dyslipidemia were also examined. Methods A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were self-reported. Results A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 +/- 1.74% and 10.9 +/- 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59-0.83). Conclusions Less than 50 % of patients with T2DM who need statins were under treatment, and only a quarter of them attained their LDL-C targets. There exists a significant gap between the guideline recommendations and the real-world evidence in the treatment of dyslipidemia in T2DM.